Section 152.34 — Health Care Facilities.
152.34 HEALTH CARE FACILITIES. (a) Health care facilities licensed under chapter 144A, hospice providers licensed under chapter 144A, boarding care homes or supervised living facilities licensed under section 144.50, assisted living facilities, facilities owned, controlled, managed, or under common control with hospitals licensed under chapter 144, and other health facilities licensed by the commissioner of […]
Section 152.35 — Fees; Deposit Of Revenue.
152.35 FEES; DEPOSIT OF REVENUE. (a) The commissioner shall collect an enrollment fee of $200 from patients enrolled under this section. If the patient provides evidence of receiving Social Security disability insurance (SSDI), Supplemental Security Income (SSI), veterans disability, or railroad disability payments, or being enrolled in medical assistance or MinnesotaCare, then the fee shall […]
Section 152.36 — Impact Assessment Of Medical Cannabis Therapeutic Research.
152.36 IMPACT ASSESSMENT OF MEDICAL CANNABIS THERAPEUTIC RESEARCH. Subdivision 1. Task force on medical cannabis therapeutic research. (a) A 23-member task force on medical cannabis therapeutic research is created to conduct an impact assessment of medical cannabis therapeutic research. The task force shall consist of the following members: (1) two members of the house of […]
Section 152.37 — Financial Examinations; Pricing Reviews.
152.37 FINANCIAL EXAMINATIONS; PRICING REVIEWS. Subdivision 1. Financial records. A medical cannabis manufacturer shall maintain detailed financial records in a manner and format approved by the commissioner, and shall keep all records updated and accessible to the commissioner when requested. Subd. 2. Certified annual audit. A medical cannabis manufacturer shall submit the results of an […]
Section 152.32 — Protections For Registry Program Participation.
152.32 PROTECTIONS FOR REGISTRY PROGRAM PARTICIPATION. Subdivision 1. Presumption. (a) There is a presumption that a patient enrolled in the registry program under sections 152.22 to 152.37 is engaged in the authorized use of medical cannabis. (b) The presumption may be rebutted by evidence that conduct related to use of medical cannabis was not for […]
Section 152.33 — Violations.
152.33 VIOLATIONS. Subdivision 1. Intentional diversion; criminal penalty. In addition to any other applicable penalty in law, a manufacturer or an agent of a manufacturer who intentionally transfers medical cannabis to a person other than another registered manufacturer, a patient, a registered designated caregiver or, if listed on the registry verification, a parent, legal guardian, […]
Section 152.25 — Commissioner Duties.
152.25 COMMISSIONER DUTIES. Subdivision 1. Medical cannabis manufacturer registration. (a) The commissioner shall register two in-state manufacturers for the production of all medical cannabis within the state. A registration agreement between the commissioner and a manufacturer is nontransferable. The commissioner shall register new manufacturers or reregister the existing manufacturers by December 1 every two years, […]
Section 152.26 — Rulemaking.
152.26 RULEMAKING. (a) The commissioner may adopt rules to implement sections 152.22 to 152.37. Rules for which notice is published in the State Register before January 1, 2015, may be adopted using the process in section 14.389. (b) The commissioner may adopt or amend rules, using the procedure in section 14.386, paragraph (a), to implement […]
Section 152.261 — Rules; Adverse Incidents.
152.261 RULES; ADVERSE INCIDENTS. (a) The commissioner of health shall adopt rules to establish requirements for reporting incidents when individuals who are not authorized to possess medical cannabis under sections 152.22 to 152.37 are found in possession of medical cannabis. The rules must identify professionals required to report, the information they are required to report, […]
Section 152.27 — Patient Registry Program Established.
152.27 PATIENT REGISTRY PROGRAM ESTABLISHED. Subdivision 1. Patient registry program; establishment. (a) The commissioner shall establish a patient registry program to evaluate data on patient demographics, effective treatment options, clinical outcomes, and quality-of-life outcomes for the purpose of reporting on the benefits, risks, and outcomes regarding patients with a qualifying medical condition engaged in the […]